Technical Analysis for REXN - Rexahn Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.39 -0.42% -0.01
REXN closed down 0.42 percent on Wednesday, August 21, 2019, on 67 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical REXN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -0.42%
Volume Surge Other -0.42%
Wide Bands Range Expansion -0.42%
Oversold Stochastic Weakness -0.42%
New 52 Week Closing Low Bearish 9.63%
Narrow Range Bar Range Contraction 9.63%
New 52 Week Low Weakness 9.63%

Older signals for REXN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company’s mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn’s product candidates may be effective against multiple types of cancer, including drug resistant cancers, difficult-to-treat cancers and others, may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301.
Cancer Cancers Cancer Treatment FDA Cancer Therapies Innovative Therapies Next Generation Cancer
Is REXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.28
52 Week Low 2.16
Average Volume 26,296
200-Day Moving Average 7.7305
50-Day Moving Average 4.6263
20-Day Moving Average 3.6054
10-Day Moving Average 2.442
Average True Range 0.3161
ADX 47.66
+DI 8.5606
-DI 40.4468
Chandelier Exit (Long, 3 ATRs ) 4.5417
Chandelier Exit (Short, 3 ATRs ) 3.1083
Upper Bollinger Band 6.1596
Lower Bollinger Band 1.0512
Percent B (%b) 0.26
BandWidth 141.687469
MACD Line -0.7703
MACD Signal Line -0.677
MACD Histogram -0.0933
Fundamentals Value
Market Cap 68.02 Million
Num Shares 28.5 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -2.37
Price-to-Sales 0.00
Price-to-Book 3.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.56
Resistance 3 (R3) 2.56 2.50 2.53
Resistance 2 (R2) 2.50 2.46 2.50 2.52
Resistance 1 (R1) 2.45 2.44 2.48 2.45 2.51
Pivot Point 2.39 2.39 2.41 2.39 2.39
Support 1 (S1) 2.34 2.35 2.37 2.34 2.27
Support 2 (S2) 2.28 2.33 2.28 2.26
Support 3 (S3) 2.23 2.28 2.25
Support 4 (S4) 2.23